INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol
Phase of Trial: Phase IV
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary) ; Vilanterol/fluticasone furoate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms INCOGNIOT
- 04 Apr 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 04 Apr 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 31 Aug 2018 Biomarkers information updated